Compare Stocks → America’s worst nightmare? (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ALGXYOTCMKTS:PRTXOTCMKTS:RPBC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGXYAffinity Energy and Health$0.00$0.00▼$0.26N/A135.11800 shsN/APRTXProtalex$0.01$0.01$0.00▼$0.10N/AN/AN/AN/ARPBCRedpoint Bio$0.00+∞$0.00$0.00▼$0.00N/AN/A101,150 shs200,000 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGXYAffinity Energy and Health0.00%0.00%0.00%0.00%0.00%PRTXProtalex0.00%0.00%0.00%0.00%0.00%RPBCRedpoint Bio0.00%0.00%0.00%0.00%0.00%Crypto Millionaire Says: “Buy This $11 AI Coin.” (Ad)Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos.Find out more about this $11 AI Coin right nowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGXYAffinity Energy and HealthN/AN/AN/AN/AN/AN/AN/AN/APRTXProtalexN/AN/AN/AN/AN/AN/AN/AN/ARPBCRedpoint BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGXYAffinity Energy and HealthN/AN/AN/AN/APRTXProtalexN/AN/AN/AN/ARPBCRedpoint BioN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGXYAffinity Energy and Health$2.05MN/AN/AN/AN/AN/APRTXProtalexN/AN/AN/AN/AN/AN/ARPBCRedpoint BioN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGXYAffinity Energy and Health-$6.08MN/A0.00N/AN/AN/AN/AN/AN/APRTXProtalexN/AN/A0.00∞N/AN/AN/AN/AN/ARPBCRedpoint BioN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGXYAffinity Energy and HealthN/AN/AN/AN/AN/APRTXProtalexN/AN/AN/AN/AN/ARPBCRedpoint BioN/AN/AN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGXYAffinity Energy and HealthN/APRTXProtalexN/ARPBCRedpoint BioN/AInsider OwnershipCompanyInsider OwnershipALGXYAffinity Energy and HealthN/APRTXProtalex80.00%RPBCRedpoint Bio11.51%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALGXYAffinity Energy and HealthN/AN/AN/ANot OptionablePRTXProtalex2N/AN/ANot OptionableRPBCRedpoint BioN/AN/AN/ANot OptionablePRTX, ALGXY, and RPBC HeadlinesRecent News About These CompaniesMarch 13, 2024 | marketwatch.comCheapest Car Insurance TexasFebruary 25, 2024 | fool.comCheapest Car Insurance in Texas for February 2024January 14, 2024 | fool.comThe Best Texas Car Insurance for 2024August 27, 2023 | education.comAmelia Earhart BiographyFebruary 23, 2023 | rd.com30 Best Biography Books You Should Have Read by NowFebruary 16, 2023 | plasticstoday.comAvient Extends Bio-Based Polyolefin RangeJanuary 27, 2023 | publishersweekly.comBiography of XOctober 15, 2022 | theconversation.comAnthony Bourdain and the farce of the ‘unauthorized’ biographyMedia Sentiment Over TimeCompany DescriptionsAffinity Energy and HealthOTCMKTS:ALGXYAffinity Energy and Health Limited operates as a plant-based health and wellbeing company in Australia, India, and the United States. It engages in developing technology to produce commercial quantities of algae and medicinal cannabis for supply to algae-based nutraceuticals, animal feed and aquaculture, medicinal cannabis, and biofuels markets. The company offers FeedMe Algae, an algae-based aqua feed; and algae-based biofuels. Affinity Energy and Health Limited was founded in 2007 and is based in Subiaco, Australia.ProtalexOTCMKTS:PRTXProtalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.Redpoint BioOTCMKTS:RPBCRedpoint Bio Corporation, a development stage biotechnology company, focuses on the development of healthier foods and new approaches for the treatment of diabetes and obesity by understanding the biology of taste and its relationship to metabolism, satiety, and diabetes. It enters into a license and commercialization agreement with International Flavors and Fragrances Inc. for the development, manufacture, use, and commercialization of RP44, which is a component of the stevia plant that works as a sweetness enhancer amplifying the existing sugary sweetness in a food or beverage. The company is based in Philadelphia, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
